[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:genotyping":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Genotyping",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07555483","A Non-inferiority Pharmacokinetic and Safety\u002FTolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)",[11],"Phase 3","RECRUITING","2026-08-26T02:17:16.980188Z","2026-05-13T02:55:06.722818Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05918861","Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS",[11],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:28.016149Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT07194993","PKU Protein Requirements",[],"2026-08-26T02:16:54.044282Z","2026-04-29T02:57:57.128645Z"]